Biomarkers in Obesity: Serum Myeloperoxidase and Traditional Cardiac Risk Parameters

Abstract

Background: Chronic low-grade inflammation, combined with traditional cardiovascular risk factors, is common in obesity, providing systemic inflammation that is associated with increased cardiovascular risk. Studies have shown serum mieloperoxidase as a potential biomarker and its clinical applicability for evaluating cardiovascular risk. This study aimed to evaluate the MPO in obese individuals, with or without systemic inflammation and potential cardiovascular risk, as well as correlating MPO with some classic cardiovascular risk parameters.

Methods: Inflammatory and cardiovascular risk markers, as well as different biochemical and hematological laboratory parameters, were analyzed. The volunteers were divided into 3 groups according to the presence (hs-CRP>3 mg/L) or absence (hs-CRP<3 mg/L) of systemic inflammation and possible cardiovascular risk.

Results: MPO was significantly increased (p<0.05) in the obese individuals with systemic inflammation. A significant increase (p<0.05) in the following biochemical parameters: glucose, HbA1c, triglycerides, non-HDL, TG/HDL was observed, and a significant decrease (p<0.01) in HDL was observed. Significant increases in the counts of total leukocytes, neutrophils and monocytes (p<0.01), as well as elevated blood pressure (p<0.05), were observed in the group of obese individuals with systemic inflammation. Serum MPO levels were correlated with classic proinflammatory and cardiovascular risk parameters.

Conclusions: High serum levels of MPO were observed in obese individuals with hs-CRP above 3 mg/L, which is a classic biomarker for inflammation and cardiovascular risk, suggesting the potential role of MPO in clinical applicability for cardiovascular disease in this population. However, considering that inflammation in obesity appears to manifest as a non-classical mechanism, further studies are necessary to elucidate the role of MPO in cardiovascular events in the population with obesity.

Key words

inflammation - cardiovascular risk - obesity - myeloperoxidase

• References

• 1 Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-919
• 2 Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circulation research 2005; 96: 939-949
• 3 Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-445
• 4 Roos CJ, Quax PH, Jukema JW. Cardiovascular metabolic syndrome: Mediators involved in the pathophysiology from obesity to coronary heart disease. Biomark Med 2012; 6: 35-52
• 5 Executive summary of the third report of the national cholesterol education program (ncep) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel iii). Jama 2001; 285: 2486-2497
• 6 Vachharajani V, Granger DN. Adipose tissue: A motor for the inflammation associated with obesity. IUBMB life 2009; 61: 424-430
• 7 Saito M, Ishimitsu T, Minami J et al. Relations of plasma high-sensitivity c-reactive protein to traditional cardiovascular risk factors. Atherosclerosis 2003; 167: 73-79
• 8 Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arterosclorer Thromb Vasc Biol 2005; 25: 1102-1111
• 9 Zhang R, Brennan ML, Fu X et al. Association between myeloperoxidase levels and risk of coronary artery disease. Jama 2001; 286: 2136-2142
• 10 Baldus S, Heeschen C, Meinertz T et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445
• 11 Meuwese MC, Stroes ES, Hazen SL et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: The epic-norfolk prospective population study. J Am Coll Cardiol 2007; 50: 159-165
• 12 Wu AH. Early detection of acute coronary syndromes and risk stratification by multimarker analysis. Biomark Med 2007; 1: 45-57
• 13 Rudolph V, Goldmann BU, Bos C et al. Diagnostic value of mpo plasma levels in patients admitted for suspected myocardial infarction. Inter J Cardiol 2011; 153: 267-271
• 14 Borato DC, Parabocz GC, Ribas SR et al. Changes of metabolic and inflammatory markers in hiv infection: Glucose, lipids, serum hs-crp and myeloperoxidase. Metab Clin Exp 2012; 61: 1353-1360
• 15 Zur B, Look M, Holdenrieder S et al. Elevated plasma myeloperoxidase concentration in adults with obesity. Clin Chim Acta 2011; 412: 1891-1892
• 16 Andrade VL, Petruceli E, Belo VA et al. Evaluation of plasmatic mmp-8, mmp-9, timp-1 and mpo levels in obese and lean women. Clin Biochemistry 2012; 45: 412-415
• 17 Musaad S, Haynes EN. Biomarkers of obesity and subsequent cardiovascular events. Epidemiol Rev 2007; 29: 98-114
• 18 WHO. Obesity: Preventing and managing the global epidemic. Report of a who consultation. World Health Organization technical report series 2000; 894 i–xii 1-253
• 19 Vita JA, Brennan ML, Gokce N et al. Serum myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 2004; 110: 1134-1139
• 20 Samsamshariat SZ, Basati G, Movahedian A et al. Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease. Biomark Med 2011; 5: 377-385
• 21 Roman RM, Camargo PV, Borges FK et al. Prognostic value of myeloperoxidase in coronary artery disease: Comparison of unstable and stable angina patients. J Coron Artery Dis 2010; 21: 129-136
• 22 Kutter D, Devaquet P, Vanderstocken G et al. Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit?. Acta haematol 2000; 104: 10-15
• 23 Asselbergs FW, Reynolds WF, Cohen-Tervaert JW et al. Myeloperoxidase polymorphism related to cardiovascular events in coronary artery disease. Am J Med 2004; 116: 429-430
• 24 Nikpoor B, Turecki G, Fournier C et al. A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in french-canadians. Am Heart J 2001; 142: 336-339
• 25 Olza J, Aguilera CM, Gil-Campos M et al. Myeloperoxidase is an early biomarker of inflammation and cardiovascular risk in prepubertal obese children. Diabetes care 2012; 35: 2373-2376
• 26 Howard BV, Ruotolo G, Robbins DC. Obesity and dyslipidemia. Endocrinol Metab Clin North Am 2003; 32: 855-867
• 27 Klop B, Elte JW, Cabezas MC. Dyslipidemia in obesity: Mechanisms and potential targets. Nutrients 2013; 5: 1218-1240
• 28 Dullaart RP, Annema W, Tio RA et al. The hdl anti-inflammatory function is impaired in myocardial infarction and may predict new cardiac events independent of hdl cholesterol. Clin Chim Acta 2014; 433: 34-38
• 29 van Deventer HE, Miller WG, Myers GL et al. Non-hdl cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated ldl cholesterol in a dyslipidemic population. Clin Chem 2011; 57: 490-501
• 30 Nicholls SJ, Hazen SL. Myeloperoxidase modified lipoproteins, and atherogenesis. J Lip Res 2009; 50 Suppl S346-S351
• 31 Ostfeld R, Mookherjee D, Spinelli M et al. A triglyceride/high-density lipoprotein ratio>or=3.5 is associated with an increased burden of coronary artery disease on cardiac catheterization. J Cardiometabolic Syndr 2006; 1: 13-15
• 32 Salazar MR, Carbajal HA, Espeche WG et al. Relation among the plasma triglyceride/high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women. Am Journal Cardiology 2012; 109: 1749-1753
• 33 Murguia-Romero M, Jimenez-Flores JR, Sigrist-Flores SC et al. Plasma triglyceride/hdl-cholesterol ratio, insulin resistance, and cardiometabolic risk in young adults. J Lipid Res 2013; 54: 2795-2799
• 34 Hanak V, Munoz J, Teague J et al. Accuracy of the triglyceride to high-density lipoprotein cholesterol ratio for prediction of the low-density lipoprotein phenotype b. Am Journal Cardiology 2004; 94: 219-222
• 35 Gaziano JM, Hennekens CH, O’Donnell CJ et al. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation 1997; 96: 2520-2525
• 36 Bittner V, Johnson BD, Zineh I et al. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: A report from the women’s ischemia syndrome evaluation (wise). Am Heart J 2009; 157: 548-555
• 37 Jeppesen J, Hein HO, Suadicani P et al. Relation of high tg-low hdl cholesterol and ldl cholesterol to the incidence of ischemic heart disease. An 8-year follow-up in the copenhagen male study. Arterioscler Thromb Vasc Biol 1997; 17: 1114-1120
• 38 Esser N, Legrand-Poels S, Piette J et al. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Prac 2014; 105: 141-150
• 39 Mathew M, Tay E, Cusi K. Elevated plasma free fatty acids increase cardiovascular risk by inducing plasma biomarkers of endothelial activation, myeloperoxidase and pai-1 in healthy subjects. Cardiovascular diabetology 2010; 9: 9
• 40 Wang Q, Xie Z, Zhang W et al. Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin resistance. Diabetes 2014; 63: 4172-4185
• 41 Nijhuis J, Rensen SS, Slaats Y et al. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring, Md) 2009; 17: 2014-2018